✦ LIBER ✦

A phase III, double-blind, randomized, multicenter study evaluating the efficacy and safety of autologous human fibroblast therapy in contour deformities at 4 months

Book ID: 116583998
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 53 KB
Volume: 58
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2007.10.600

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase III, double-blind, randomized, m

A phase III, double-blind, randomized, multicenter study evaluating the efficacy and safety of autologous human fibroblast therapy in contour deformities at 6 months

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Two phase III, multicenter, double-blind

Two phase III, multicenter, double-blind, randomized, placebo-controlled trials evaluating the efficacy and safety of autologous fibroblast therapy in the treatment of nasolabial fold wrinkles

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Two phase III, multicenter, double-blind

Two phase III, multicenter, double-blind, randomized, placebo-controlled trials evaluating the efficacy and safety of autologous fibroblast therapy in the treatment of nasolabial fold wrinkles

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 42 KB

A randomized, double-blind, multicenter,

A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia

✍ Hiroyoshi Ohta, Hiroshi Oka, Chie Usui, Masayuki Ohkura, Makoto Suzuki, Kusuki N 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 370 KB

Rituximab for rheumatoid arthritis refra

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

✍ Stanley B. Cohen; Paul Emery; Maria W. Greenwald; Maxime Dougados; Richard A. Fu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 3 views

Efficacy and Safety of Canakinumab (ACZ8

Efficacy and Safety of Canakinumab (ACZ885), a Fully Human Anti-Interleukin-1b-Antibody, in Cryopyrin Associated Periodic Fever Syndrome Results of a Multicenter, Randomized, Double-blind, Phase III Study

✍ Lachman, H.; Kone-Paut, I.; Kuemmerle-Deschner, J.; Leslie, K.; Hachulla, E.; Qu 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB